Healthcare providers and industry analysts are expressing serious concerns following President Donald Trump’s announcement of extensive tariff measures that will affect medical supplies and equipment imports. The new policy, revealed Wednesday, implements a 10% baseline tariff starting April 5, with additional country-specific duties beginning April 9.
The measures will impact essential medical items including syringes, diagnostic equipment, X-ray machines, and protective gear, according to Fitch Ratings’ Kevin Holloran. The inclusion of medical devices represents a departure from previous practices that typically exempted critical healthcare products.
Healthcare facilities face particular challenges from these tariffs since many have long-term contracts with payers that prevent them from passing increased costs to patients. Without the ability to offset higher expenses, hospitals may see declining operating income unless they can find alternative cost savings or revenue sources.
The American Hospital Association had previously sought exemptions for medical supplies, arguing that many items couldn’t feasibly be produced domestically. Despite these efforts, and similar appeals from medical device trade group AdvaMed, the administration moved forward with the broad tariffs.
Providence health system estimates the tariffs could increase their annual costs by $10-25 million. Their CEO Erik Wexler highlighted existing supply chain vulnerabilities, citing recent shortages of IV fluids following hurricane damage to manufacturing facilities. He warned that combined with potential Medicaid cuts, the tariffs could severely impact healthcare access.
The Florida Hospital Association’s Mary Mayhew noted that hospitals face limited options for adapting their supply chains. Storage constraints and product shelf life issues make it impractical to maintain large inventories, while existing group purchasing contracts restrict flexibility in finding new suppliers.
The impact extends beyond hospitals to medical practices, which are already managing Medicare reimbursement reductions and inflation pressures. Anders Gilberg of the Medical Group Management Association expressed concern about practices’ ability to absorb additional costs without the option to increase prices.
Some analysts, including J.P. Morgan, suggest that existing
fixed-price contracts may temporarily shield providers from immediate effects. Northwell Health, for instance, doesn’t anticipate near-term impacts due to current contract terms.
Diabetes technology companies appear particularly vulnerable to the tariffs. Morningstar analyst Debbie Wang identified Dexcom, Insulet, and especially Tandem Diabetes as potentially affected firms, with Tandem facing greater exposure due to its reliance on international manufacturing.
Larger medical device manufacturers like Boston Scientific and Edwards Lifesciences are expected to mitigate impacts by adjusting their manufacturing locations. However, William Blair analysts note that the full cost implications won’t become clear until 2026 when many purchasing contracts come up for renewal.
The healthcare sector now faces significant uncertainty as
organizations evaluate their options. The Florida Hospital
Association’s Mayhew described the situation as “uncharted waters,” with daily changes making it difficult to develop long-term
strategies.
While pharmaceutical products received exemptions from the tariffs, the broader healthcare industry continues pushing for similar carve-outs for medical devices. The AHA’s Akin Demehin emphasized the need to balance domestic supply chain strengthening with maintaining consistent patient care access, particularly for products already experiencing shortages.
Be First to Comment